Advances in brain targeting and drug delivery of anti-HIV therapeutic agents

Expert Opinion on Drug Delivery

Volumn 10, Issue 7, 2013, Pages 973-985

  Al Ghananeem, Abeer M ^a   Smith, Michael ^a   Coronel, Maria L ^a   Tran, Hieu ^a  

^a Sullivan University   (United States)

Author keywords

AID; BBB; Brain targeting; CNS; Dementia; HIV; Nanotechnology; Nasal delivery; Prodrug

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; GLUTAMATE AMMONIA LIGASE; GLUTAMIC ACID; GLUTAMINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; INDINAVIR; LEUKOTRIENE A4; LIPOSOME; MEMANTINE; MINOCYCLINE; NELFINAVIR; NEUROTOXIN; PANTOTHENIC ACID; PENICILLIN DERIVATIVE; PROBENECID; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SELEGILINE; STAVUDINE; TRANSACTIVATOR PROTEIN; VALSPODAR; VIRUS DNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; CHEMICAL MODIFICATION; DNA REPAIR; DRUG ACTIVITY; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL LITERATURE; NANOTECHNOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; VIRUS PATHOGENESIS; VIRUS REPLICATION;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY;

EID: 84879331845     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.781999     Document Type: Review

References (114)

1. Pang S, Koyangi Y, Miles S, et al. High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature 1990;34:85-9
2. Koppel BS, Wormser GP, Tuchman AJ, et al. Central nervous system involvement in patients with acquired immune deficiency syndrome (AIDS). Acta Neurol Scand 1985;71:337-53
3. Carne CA; ABC of AIDS. Neurological manifestations. Br Med J 1987;294:1399-401
4. Anderson BD, Hoesterey BL, Baker DC, Galinsky RE. Uptake kinetics of 2,3-dideoxyinosine into brain and cerebrospinal fluid of rats: intravenous infusion studies. J Pharm Exp Therap 1989;253:113-18
5. Minagar A, Commins D, Alexander JS, et al. NeuroAIDS: characteristics and diagnosis of the neurological complications of Aids. Mol Diagn Ther 2008;12:25-43
6. Gray F, Adle-Biassette H, Chretien F, et al. Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-Associated disorders and modifications according to treatments. Clin Neuropathol 2001;20:146-55 . An important reference detailing the pathogenesis of HIV harbored in brain tissue.
7. Spencer DC, Price RW. Human immunodeficiency virus and the central nervous system. Annu Rev Microbiol 1992;46:655-93
8. Lipton SA, Gendelman HE. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 1995;332:934-40
9. Lesniak MS, Brem H. Targeted therapy for brain tumors. Nat Rev Drug Discov 2004;3:499-508
10. Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomed 2009;4:557-74
11. Begley DJ. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 1996;48:136-46
12. Frey WH. Bypassing the blood-brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv Technol 2002;2:46-9
13. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993;57(1):183-289
14. Rao KS, Ghorpade A, Labhasetwar V. Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv 2009;6(8):771-84
15. Skalka AM, Katz RA. Retroviral DNA integration and the DNA damage response. Cell Death Differ 2005;12(1):971-8
16. Engelman A. The roles of cellular factors in retroviral integration. Curr Top Microbiol Immunol 2003;281:209-38
17. Lipton SA. HIV related neurotoxicity. Brain Pathol 1991;1(3):193-9
18. Visalli V, Muscoli C, Sacco I, et al. N-Acetylcysteine prevents HIV gp 120-related damage of human cultured astrocytes: correlation with glutamine synthase dysfunction. Neuro Sci 2007;8(1):106
19. Dreyer EB, Kaiser PK, Offermann JT, et al. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990;248(4953):364-7
20. Lipton SA. AIDS-related dementia and calcium homeostasis. Ann NY Acad Sci 1994;747:205-24
21. Reger M, Welsh R, Razani J, et al. A meta-Analysis of the neuropsychological sequelae of HIV infection. J Int Neuropsychol Soc 2002;8(3):410-24
22. McArthur JC, Sacktor N, Selnes O. Review human immunodeficiency virus-Associated dementia. Semin Neurol 1999;19(2):129-50
23. Kramer-Hämmerle S, Rothenaigner I, Wolff H, et al. Review cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 2005;111(2):194-213
24. Song L, Nath A, Geiger JD, et al. Human immunodeficiency virus type 1 Tat protein directly activates neuronal N-methyl-D-Aspartate receptors at an allosteric zinc-sensitive site. J Neurovirol 2003;9(3):399-403
25. András IE, Pu H, Deli MA, et al. HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res 2003;74(2):255-65
26. Li W, Galey D, Mattson MP, Nath A. Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox Res 2005;8:119-34
27. Lindl K, Marks D, Kolson D, Jordan-Sciutton K. HIV-Associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol 2010;5(3):294-309
28. Palmer A. The role of the blood-CNS barrier in CNS disorders and their treatment. Neurobiol Dis 2010;37:13-12
29. Eval S, Hsiao P, Unadkat JD. Drug interactions at the blood brain-barrier: fact or fantasy? Pharmacol Ther 2009;123(1):80-104
30. Romeo VD, deMeireles J, Sileno AP, et al. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev 1998;29:89-116
31. Chien YW, Chang SF. Intranasal drug delivery for systemic medications. Crit Rev Ther Drug Carrier Syst 1987;4(2):67-194
32. Charlton ST, Davis SS, Illum L. Evaluation of effect of ephedrine on the transport of drugs from the nasal cavity to the systemic circulation and the central nervous system. J Drug Target 2007;15(5):370-7
33. Al-Ghananeem AM, Malkawi AH, Crooks PA. Bioavailability of D9-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. Drug Dev Ind Pharm 2011;37(3):329-34
34. Hussain AA. Intranasal drug delivery. Adv Drug Deliv Rev 1998;29:39-49
35. Al-Ghananeem AM, Traboulsi AA, Dittert LW, Hussain AA. Targeted brain delivery of 17b-estradiol via nasally administered water soluble prodrugs. AAPS PharmSciTech 2002;3:1
36. Illum L. Is nose-to-brain transport of drugs in man a reality. J Pharm Pharmacol 2003;56:3-17
37. Sakaue G, Hiroi T, Nakagawa Y, et al. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-Liposome Induces antigen-specific CTLs and neutralizing antibody responses. J Immunol 2003;170:495-502
38. Al-Ghananeem AM, Saeed H, Florence R, et al. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target 2010;18(5):381-8
39. Seki T, Sato N, Hasegawa T, et al. Nasal absorption of zidovudine and its transport to cerebrospinal fluid in rats. Biol Pharm Bull 1994;17(8):1135-7
40. Ved PM, Kim K. Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain. Int J Pharm 2011;411(1-2):1-9
41. Yang Z, Huang Y, Gan G, Sawchuk RJ. Microdialysis evaluation of the brain distribution of stavudine following intranasal and intravenous administration to rats. J Pharm Sci 2005;94(7):1577-88
42. Misral A, Ganesh S, Shahiwala A, Shrenik P. Drug delivery to the central nervous system. J Pharm Sci 2003;6(2):252-73
43. Pardridge WM. Recent advances in blood brain-barrier transport. Annu Rev Pharmacol Toxicol 1988;28:25-39
44. Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 2002;41:81-92
45. Joshi S, Ergin A, Wang M, et al. Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy. J Neurooncol 2011;104(1):11-19
46. Ding D, Kanaly CW, Bigner DD, et al. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. J Neurooncol 2010;98(1):1-7
47. Brem H, Langer R. Polymer based drug delivery to the brain. Sci Med 1996;3(4):1-11
48. Brem H, Gabikian P. Biodegradable polymer implants to treat brain tumors. J Control Release 2001;74:63-7
49. Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998;58(4):672-84
50. Golden PL, Maccagnan TJ, Pardridge WM. Human blood-brain barrier leptin receptor: binding and endocytosis in isolated human brain microvessels. J Clin Invest 1997;99:14-18
51. Tamai I, Sai Y, Kobayashi H, et al. Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. J Pharmacol Exp Ther 1997;280:410-15
52. Harbaugh RE, Saunders RL, Reeder RF. Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery 1988;23(6):693-8
53. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975;195:73-83
54. Huang TY, Arita N, Hayakawa T, Ushio Y. ACNU, MTX and 5-FU penetration of rat brain tissue and tumors. J Neurooncol 1999;45:9-17
55. Baratchi S, Kanwar Rupinder K, Khoshmanesh K, et al. Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases. Curr Nano Sci 2009;5:15-25
56. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47(1):65-81
57. Dandagi P, Patel P, Gadad A, Aravapalli AK. RES and brain targeting stavudine-loaded solid lipid nanoparticles for AIDS therapy. Asian J Pharm 2012;6(2):116-23
58. Chattopadhyay N, Zastre J, Wong HL, et al. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res 2008;25:2262-71
59. Bender AR, Von Briesen H, Kreuter J, et al. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob Agents Chemother 1996;40(6):1467-71
60. Vyas TK, Shah L, Amiji MM. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv 2006;3(5):613-28
61. Kinman L, Bui T, Larsen K, et al. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquired Immune Defic Syndr 2006;42(2):155-61
62. Dou H, Morehead J, Destache CJ, et al. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 2007;358(1):148-58
63. Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev 2010;62(4-5):503-17
64. Saiyed ZM, Gandhi NH, Nair MP. Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier. Int J Nanomedicine 2010;5:157-66
65. Saiyed ZM, Gandhi NH, Nair MP. AZT 5'-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells. J Neurovirol 2009;15(4):343-7
66. Wu D, Clement JG, Pardridge WM. Low blood-brain barrier permeability to azidothymidine (AZT), 3TC-, and thymidine in the rat. Brain Res 1998;791(1-2):313-16
67. Thomas née Williams SA, Segal MB. Identification of a saturable uptake system for deoxyribonucleosides at the blood-brain and blood-cerebrospinal fluid barriers. Brain Res 1996;741(1-2):230-9
68. Thomas SA, Segal MB. The passage of azidodeoxythymidine into and within the central nervous system: does it follow the parent compound, thymidine? J Pharmacol Exp Ther 1997;281(3):1211-18
69. Dykstra KH, Arya A, Arriola DM, et al. Microdialysis study of zidovudine (AZT) transport in rat-brain. J Pharmacol Exp Ther 1993;267(3):1227-36
70. Masereeuw R, Jaehde U, Langemeijer MWE, et al. In-vitro and in-vivo transport of zidovudine (AZT) across the blood-brain-barrier and the effect of transport inhibitors. Pharm Res 1994;11(2):324-30
71. Takasawa K, Terasaki T, Suzuki H, et al. In vivo evidence for carrier-mediated efflux transport of 3'-Azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J Pharmacol Exp Ther 1997;281(1):369-75
72. Kawaguchi T, Ishikawa K, Seki T, et al. Ester prodrugs of zidovudine. J Pharm Sci 1990;79(6):531-3
73. Aggarwal SK, Gogu SR, Rangan SRS, et al. Synthesis and biological evaluation of prodrugs of zidovudine. J Med Chem 1990;33(5):1505-10
74. Namane A, Gouyette C, Fillion MP, et al. Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. J Med Chem 1992;35(16):3039-44
75. McGuigan C, Pathirana RN, Balzarini J, et al. Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. J Med Chem 1993;36(8):1048-52
76. Hostetler KY, Stuhmiller LM, Lenting HBM, et al. Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides. J Biol Chem 1990;265(11):6112-17
77. Chu CK, Bhadti VS, Doshi KJ, et al. Brain targeting of anti-HIV nucleosides-synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-Azido-2',3'-dideoxyuridine and 3'-Azido-3'-deoxythymidine. J Med Chem 1990;33(8):2188-92
78. Piantadosi C, Marasco CJ, Morrisnatschke SL, et al. Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity. J Med Chem 1991;34(4):1408-14
79. Wang L, Morin KW, Kumar R, et al. In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5-halo-6-methoxy (or ethoxy)-5,6-dihydro-3'-Azido-3'-deoxythymidine diastereomers as potential prodrugs of 3'-Azido-3'-deoxythymidine. J Med Chem 1996;39(4):826-33
80. Kumar R, Wang LL, Wiebe LI, et al. Synthesis, in-vitro biological stability, and anti-HIV activity of 6-halo-6-Alkoxy (or azido)-5,6-dihydro-3'- Azido-3'-deoxythymidine diastereomers as potential prodrugs to 3'-Azido-3'-deoxythymidine (AZT). J Med Chem 1994;37(25):4297-306
81. Johnson MD, Anderson BD. Localization of purine metabolizing enzymes in bovine brain microvessel endothelial cells: an enzymatic blood-brain barrier for dideoxynucleosides? Pharm Res 1996;13(12):1881
82. Masood R, Ahluwalia GS, Cooney DA, et al. 2'-fluoro-2',3'- dideoxyarabinosyladenine-A metabolically stable analog of the antiretroviral agent 2',3'-dideoxyadenosine. Mol Pharmacol 1990;37(4):590-6
83. Marquez VE, Tseng CKH, Mitsuya H, et al. Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV. J Med Chem 1990;33(3):978-85
84. Johnson MD, Chen J, Anderson BD. Investigation of the mechanism of enhancement of central nervous system delivery of 2',-beta-fluoro-2',3'- dideoxyinosine via a blood-brain barrier adenosine deaminase-Activated prodrug. Drug Metab Dispos 2002;30(2):191-8
85. Maiti KK, Jeon OY, Lee WS, et al. Design, synthesis, and membrane-translocation studies of inositol-based transporters. Angew Chem Int Ed Engl 2006;45(18):2907-12
86. Im J, Kim W, Kim KT, et al. Preparation of a 3'-Azido-3'-deoxythymidine (AZT) derivative, which is blood-brain barrier permeable. Chem Commun 2009;31:4669-71
87. Gelbard HA, Nottet H, Swindells S, et al. Platelet-Activating-factor-A candidate human-immunodeficiency-virus type 1-induced neurotoxin. J Virol 1994;68(7):4628-35
88. Perry SW, Hamilton JA, Tjoelker LW, et al. Platelet-Activating factor receptor activation-An initiator step in HIV-1 neuropathogenesis. J Biol Chem 1998;273(28):17660-4
89. Bito H, Nakamura M, Honda Z, et al. Platelet-Activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in hippocampal neurons. Neuron 1992;9(2):285-94
90. Martin M, Serradji N, Dereuddre-Bosquet N, et al. PMS-601, a new platelet-Activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages. Antimicrob Agents Chemother 2000;44(11):3150-4
91. Sallem W, Serradji N, Dereuddre-Bosquet N, et al. Structure-Activity relationships in platelet-Activating factor. Part 14: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 activity. Bioorg Med Chem 2006;14(23):7999-8013
92. Serradji N, Martin M, Bensaid O, et al. Structure-Activity relationships in platelet-Activating factor.
93. Synthesis and biological evaluation of platelet-Activating factor antagonists with anti-HIV-1 activity. J Med Chem 2004;47(25):6410-19
94. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000;89(11):1371-88
95. Farese-Di Giorgio A, Rouquayrol M, Greiner J, et al. Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavir. Antivir Chem Chemother 2000;11(2):97-110
96. Rouquayrol M, Gaucher W, Greiner J, et al. Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir. Carbohydr Res 2001;336(3):161-80
97. Rouquayrol M, Gaucher B, Roche D, et al. Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 Cell monolayers. Pharm Res 2002;19(11):1704-12
98. Berezovskaya YV, Chudinov MV. Ester derivatives of nucleoside inhibitors of reverse transcriptase:
99. Molecular transport systems for 3'-Azido-3'-deoxythymidine and 2', 3'-didehydro-3'-deoxythymidine. Bioorg Khim 2005;31(4):303-19
100. Gottesman MM, Pastan I. Biochemistry of multidrug-resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427
101. Polli JW, Jarrett JL, Studenberg SD, et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999;16(8):1206-12
102. Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research (vol 82, pg A99, 2009). Antiviral Res 2009;84(2):203-3
103. Sosnik A, Chiappetta DA, Carcaboso AM. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J Control Release 2009;138(1):2-15
104. Drewe J, Gutmann H, Fricker G, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999;57(10):1147-52
105. Fishman RA. Blood-brain and CSF barriers to penicillin and related organic acids. Arch Neurol 1966;15(2):113
106. Spector R, Goetzl EJ. Leukotriene-c4 transport and metabolism in the central-nervous-system. J Neurochem 1986;46(4):1308-12
107. Spector R. Pantothenic-Acid transport and metabolism in the central-nervous-system. Am J Physiol 1986;250(2):R292-7
108. Hedaya MA, Sawchuk RJ. Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit. J Pharm Sci 1989;78(9):716-22
109. Hedaya MA, Elmquist WF, Sawchuk RJ. Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. Pharm Res 1990;7(4):411-17
110. Galinsky RE, Flaharty KK, Hoesterey BL, et al. Probenecid enhances central-nervous-system uptake of 2',3'-dideoxyinosine by inhibiting cerebrospinal-fluid efflux. J Pharmacol Exp Ther 1991;257(3):972-8
111. Miller DW, Batrakova EV, Waltner TO, et al. Interactions of Pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjug Chem 1997;8(5):649-57
112. Spitzenberger TJ, Heilman D, Diekmann C, et al. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab 2007;27(5):1033-42
113. Shaik N, Pan G, Elmquist WF. Interactions of Pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J Pharm Sci 2008;97(12):5421-33
114. Namanja HA, Emmert D, Davis DA, et al. Toward eradicating HIV reservoirs in the brain: inhibiting p-glycoprotein at the blood-brain barrier with prodrug abacavir dimers. J Am Chem Soc 2012;134(6):2976-80